Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2007

View Archived Issues

Immune responses, clinical benefit seen with T-cell vaccination in rheumatoid arthritis

Novel therapeutic agents for respiratory disorders disclosed in recent patent literature

Recent patents describe novel agents for anxiety, depression, psychosis etc.

Novel treatment options for thrombotic disorders reported in recent patents

Phase II results suggest tetomilast is active in ulcerative colitis

Statins linked to lower risk of infection-related mortality

5-HT4 activation inhibits Abeta secretion and increases survival of neurons oversecreting Abeta

Pharmacopeia and Organon establish new alliance

VASTox signs chemical genomics agreements

RotaTeq prescribing information updated

Effect of rifalazil investigated on atherosclerotic changes in the carotid artery

Smallpox drug SIGA-246 studied in phase I trial

Agreement to study FavId with Leukine in B-cell NHL

Sanofi pasteur licenses ChimeriVax-JE vaccine from Acambis

FDA extends review of rimonabant

Phase I study under way for DARA compound PS-433540

AndroScience files IND for ASC-J9 for acne

Tikvah Therapeutics licenses compounds for anxiety-related disorders

BrainStorm's adult stem cell technology studied in Parkinson's disease in primates

Treatment under way in phase II study of Litx therapy in glioma

Completion of phase III studies for Metvix with Aktilite

IPI-504 studied for NSCLC

Teverelix LA has same effect on testosterone suppression in normal and obese subjects

Bavituximab shows signs of dose dependent antiviral activity in chronic HCV

FDA accepts for review two sNDAs for Januvia

Roche files for Tamiflu 30 and 45 mg capsules in Europe

Satraplatin NDA filing completed

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...